1. Home
  2. PRT vs LSTA Comparison

PRT vs LSTA Comparison

Compare PRT & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PermRock Royalty Trust Trust Units

PRT

PermRock Royalty Trust Trust Units

HOLD

Current Price

$2.07

Market Cap

25.3M

Sector

Energy

ML Signal

HOLD

Logo Lisata Therapeutics Inc.

LSTA

Lisata Therapeutics Inc.

HOLD

Current Price

$3.75

Market Cap

28.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRT
LSTA
Founded
2017
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Misc Health and Biotechnology Services
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.3M
28.9M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
PRT
LSTA
Price
$2.07
$3.75
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
74.2K
62.4K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
13.45%
N/A
EPS Growth
N/A
20.42
EPS
N/A
N/A
Revenue
N/A
$35,283,868.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.78
N/A
Revenue Growth
N/A
56.90
52 Week Low
$1.82
$1.81
52 Week High
$4.28
$5.07

Technical Indicators

Market Signals
Indicator
PRT
LSTA
Relative Strength Index (RSI) 38.04 62.41
Support Level $1.82 $3.06
Resistance Level $3.57 $4.84
Average True Range (ATR) 0.13 0.15
MACD 0.03 0.07
Stochastic Oscillator 66.67 67.02

Price Performance

Historical Comparison
PRT
LSTA

About PRT PermRock Royalty Trust Trust Units

PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.

Share on Social Networks: